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Background. Prior trials of the JOSTENT PTFE stent-graft in pts with diseased saphenous vein grafts (SVGs) did not mandate high-pressure 
implantation or prolonged dual anti-platelet therapy, and were limited by short-term follow-up.
Methods. To overcome these limitations, 243 pts at 47 centers with 1-2 discrete SVG lesions were prospectively randomized to JOSTENT 
implantation (≥18 atm.) vs. bare metal stents (BMS). JOSTENT pts were treated with aspirin indefinitely and clopidogrel for ≥8 months. Routine 
angiographic follow-up was performed at 8 months, and all pts were followed for 5 years.
Results. The primary endpoint of in-lesion binary restenosis occurred in 31.8% of lesions treated with the JOSTENT vs. 28.4% with BMS (RR [95%CI] 
= 1.12 [0.72,1.75], p=0.63). The major secondary endpoint of 9 month target vessel failure (death, MI or TVR) occurred in 32.2% of pts treated with 
the JOSTENT vs. 22.1% with BMS (HR [95%CI] = 1.54 [0.94,2.53], p=0.08). During long-term follow-up significantly more events accrued with the 
JOSTENT such that by 5 years TVF had occurred in 68.3% of JOSTENT pts vs. 51.8% of BMS pts (HR [95%CI] = 1.59 [1.13,2.23], p=0.007) (Table).
Conclusions. The long-term prognosis for diseased SVGs requiring PCI is dismal. Despite high pressure implantation and prolonged dual anti-platelet 
therapy, the JOSTENT PTFE stent-graft results in inferior outcomes compared to BMS, a finding which becomes more evident with longer-term follow-up. 
JOSTENT (N=115 patients) Bare metal stent (N=128 patients) P value
Target vessel failure
- 1 year 39.2% (45) 28.0% (34) 0.07
- 3 years 60.2% (68) 37.0% (44) 0.001
- 5 years 68.3% (76) 51.8% (59) 0.007
Death, all-cause
- 1 year 7.0% (8) 5.0% (6) 0.51
- 3 years 18.8% (21) 11.2% (13) 0.13
- 5 years 29.8% (32) 22.3% (24) 0.20
Myocardial infarction
- 1 year 14.2% (16) 11.3% (14) 0.53
- 3 years 21.0% (23) 14.1% (17) 0.21
- 5 years 26.2% (27) 17.4% (20) 0.16
Target lesion revascularization
- 1 year 20.9% (23) 16.9% (20) 0.46
- 3 years 37.4% (40) 21.8% (25) 0.02
- 5 years 43.9% (45) 29.6% (32) 0.04
Target vessel revascularization
- 1 year 28.2 (31) 21.1% (25) 0.22
- 3 years 41.9% (45) 26.8% (31) 0.03
- 5 years 48.2% (50) 33.3% (37) 0.04
Stent thrombosis
- 1 year 5.4% (6) 3.4% (4) 0.44
- 3 years 8.3% (9) 3.4% (4) 0.13
- 5 years 10.9% (11) 5.6% (6) 0.16
Target vessel occlusion
- 1 year 5.4% (6) 1.6% (2) 0.12
- 3 years 11.2% (12) 3.5% (4) 0.03
- 5 years 14.0% (14) 7.8% (8) 0.13
